Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2(+ )breast cancer

por Cortés-Funes, H, Mendiola, C, Manso, L, Ciruelos, E
Publicado 2009

Circulating epithelial tumor cells in patients with metastatic breast cancer treated with bevacizumab

por Manso, L, Ciruelos, E, Rodríguez, A, Diaz, J, Mendiola, C, López-Martín, JA, Cortes-Funes, H
Publicado 2009

Getting deep in the luminal B breast cancer subtype and its ki67 cut-off value

por Ciruelos, E, Castaneda, C, Pascual, T, Andrés, E, Gomez, HL, Manso, L, Valdivieso, N, Ghanem, I, Cortes-Funes, H
Publicado 2011

Lobular carcinoma of the breast: outcome of 205 patients

por Vega, E, Ciruelos, E, Valdiviezo, N, Mendiola, C, Manso, L, Ghanem, I, Dorta, M, Pascual, T, Flores, C, Cortés-Funes, H
Publicado 2011

SEOM clinical guidelines in early stage breast cancer (2018)

por Ayala de la Peña, F., Andrés, R., Garcia-Sáenz, J. A., Manso, L., Margelí, M., Dalmau, E., Pernas, S., Prat, A., Servitja, S., Ciruelos, E.
Publicado 2018

Genomic landscape and immune-related gene expression profiling of epithelial ovarian cancer after neoadjuvant chemotherapy

por Lodewijk, I., Bernardini, A., Suárez-Cabrera, C., Bernal, E., Sánchez, R., Garcia, J. L., Rojas, K., Morales, L., Wang, S., Han, X., Dueñas, M., Paramio, J. M., Manso, L.
Publicado 2022

SEOM clinical guideline in ovarian cancer (2020)

por Redondo, A., Guerra, E., Manso, L., Martin-Lorente, C., Martinez-Garcia, J., Perez-Fidalgo, J. A., Varela, M. Q., Rubio, M. J., Barretina-Ginesta, M. P., Gonzalez-Martin, A.
Publicado 2021

Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxe...

por Manso, L, Ciruelos, E, Codes, M, De la Haba, J, Galan, A, Baena, J, Jaen, A, Gil, M, Murias, A, Blancas, I, Gonzalez, E, Perez, D, Bayo, JL, Mel, J, Garcia-Martinez, E, Cubedo, R, Salvador, J
Publicado 2011

Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer

por Griguolo, G., Serna, G., Pascual, T., Fasani, R., Guardia, X., Chic, N., Paré, L., Pernas, S., Muñoz, M., Oliveira, M., Vidal, M., Llombart-Cussac, A., Cortés, J., Galván, P., Bermejo, B., Martínez, N., López, R., Morales, S., Garau, I., Manso, L., Alarcón, J., Martínez, E., Villagrasa, P., Prat, A., Nuciforo, P.
Publicado 2021

Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A

por Mouron, S., Bueno, M. J., Lluch, A., Manso, L., Calvo, I., Cortes, J., Garcia-Saenz, J. A., Gil-Gil, M., Martinez-Janez, N., Apala, J. V., Caleiras, E., Ximénez-Embún, Pilar, Muñoz, J., Gonzalez-Cortijo, L., Murillo, R., Sánchez-Bayona, R., Cejalvo, J. M., Gómez-López, G., Fustero-Torre, C., Sabroso-Lasa, S., Malats, N., Martinez, M., Moreno, A., Megias, D., Malumbres, M., Colomer, R., Quintela-Fandino, M.
Publicado 2022